The novel psychoactive substance 25E-NBOMe induces reward-related behaviors via dopamine D1 receptor signaling in male rodents
Young-Jung Kim, Wun-A Kook, Shi-Xun Ma, Bo-Ram Lee, Yong-Hyun Ko, Seon-Kyung Kim, Youyoung Lee, Jae-Gyeong Lee, Sooyeun Lee, Kyeong-Man Kim, Seok-Yong Lee, Choon-Gon Jang
Archives of Pharmacal Research April 1, 2024 DOI: 10.1007/s12272-024-01491-4 via Springer Nature
Summary
AI-generated from the abstract25E-NBOMe, a novel psychoactive substance, induces conditioned place preference in male mice and self-administration in male rats, indicating abuse potential. The drug enhances dopamine transporter and dopamine D1 receptor expression in the nucleus accumbens, reduces dopamine levels, and activates intracellular signaling pathways. Blocking the D1 receptor or inhibiting D1 receptor-expressing neurons attenuates the conditioned place preference. The drug also produces hallucinogenic effects via serotonin 2A receptor activity, as shown by the head twitch response. These findings suggest that D1 receptor signaling may govern the addictive potential of 25E-NBOMe.
Study at a glance
| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Male mice and male rats |
| Intervention | 25E-NBOMe |
| Keywords | 25e-nbome Novel psychoactive substance Reward Dopamine d1 receptor Hallucinogenic effect |
| Citations | 3 |
| Key finding | 25E-NBOMe induces conditioned place preference and self-administration, with dopamine D1 receptor signaling in the nucleus accumbens mediating its abuse potential. |
Abstract
Novel psychoactive substances (NPSs) are new psychotropic drugs designed to evade substance regulatory policies. 25E-NBOMe (2-(4-ethyl-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine) has recently been identified as an NPS, and its recreational misuse has been reported to be rapidly increasing. However, the psychopharmacological effects and mechanisms of 25E-NBOMe have not been studied. We examined the abuse potential of 25E-NBOMe using the conditioned place preference in male mice and self-administration paradigms in male rats. Additionally, immunoblot assay, enzyme-linked immunosorbent assay, and microdialysis were used to determine the molecular effects of 25E-NBOMe in the nucleus accumbens (NAc). Our data demonstrated that 25E-NBOMe induces conditioned place preference, and the dopaminergic signaling in the NAc mediates these. Following 25E-NBOMe administration, expression of dopamine transporter and dopamine D1 receptor (D1DR) were enhanced in the NAc of male mice, and NAc dopamine levels were reduced in both male mice and rats. Induction of intracellular dopaminergic pathways, DARPP32, and phosphorylation of CREB in the NAc of male mice was also observed. Significantly, pharmacological blockade of D1DR or chemogenetic inhibition of D1DR-expressing medium spiny neurons in the NAc attenuated 25E-NBOMe-induced conditioned place preference in male mice. We also examined the hallucinogenic properties of 25E-NBOMe using the head twitch response test in male mice and found that this behavior was mediated by serotonin 2A receptor activity. Our findings demonstrate that D1DR signaling may govern the addictive potential of 25E-NBOMe. Moreover, our study provides new insights into the potential mechanisms of substance use disorder and the improvement of controlled substance management.